<DOC>
	<DOCNO>NCT00310024</DOCNO>
	<brief_summary>This phase I trial study side effect best dose vorinostat give together bortezomib treat patient relapsed refractory multiple myeloma . Vorinostat bortezomib may stop growth cancer cell block enzymes need cell growth . Giving vorinostat together bortezomib may kill cancer cell</brief_summary>
	<brief_title>Vorinostat Bortezomib Treating Patients With Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose ( MTD ) vorinostat ( SAHA ) give together bortezomib patient relapse refractory multiple myeloma ( MM ) . II . Determine toxicity regimen patient . SECONDARY OBJECTIVES : I . Determine whether give SAHA together bortezomib inhibits histone deacetylation normal cell ( buccal mucosal cell and/or peripheral blood monocyte ) well MM cell . II . Evaluate effect dexamethasone give together SAHA bortezomib . III . Explore molecular mechanism involve apoptosis MM mediate SAHA bortezomib . IV . Correlate change histone acetylation clinical outcome patient treat regimen . OUTLINE : This multicenter , dose escalation study vorinostat ( SAHA ) . Patients receive bortezomib IV day 1 , 4 , 8 , 11 follow oral SAHA twice daily day 4-11 . Beginning course 3 , patient may receive low-dose oral dexamethasone day 4-8 . Treatment repeat every 21 day 8 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos SAHA maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . An additional cohort 10 patient receive treatment MTD . Patients undergo blood collection tumor biopsy periodically study pharmacologic biomarker correlative study . After completion study treatment , patient follow least month .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Histologically clinically confirm multiple myeloma Relapsed refractory disease prior chemotherapy transplantation* Measurable disease , define quantitative immunoglobulin level serum and/or urine bone marrow plasmacytosis Nonsecretory disease allow provide MRI positron emission tomography CT scan accurately measure least one plasmacytoma lesion No known CNS involvement Life expectancy &gt; 3 month ECOG performance status ( PS ) 02 OR Karnofsky PS 60100 % Absolute neutrophil count ≥ 1,000/mm³ ( unless myelosuppression secondary bone marrow plasmacytosis [ &gt; 80 % involvement ] ) Platelet count ≥ 50,000/mm³ ( unless myelosuppression secondary bone marrow plasmacytosis [ &gt; 80 % involvement ] ) Bilirubin ≤ 2 time upper limit normal ( ULN ) AST ALT ≤ 2 time ULN Creatinine &lt; 2 mg/dL OR creatinine clearance &gt; 40 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Able swallow pill Patients history seizure eligible provide seizure adequate control nonenzyme induce anticonvulsant medication No history allergic reaction attribute study agent No sensory motor neuropathy ≥ grade II No uncontrolled current illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness social situation would limit study compliance No grade 3 QT prolongation ( i.e. , &gt; 500 msec ) baseline See Disease Characteristics Prior bortezomib allow At least 2 week since prior therapy multiple myeloma Concurrent growth factor ( filgrastim [ GCSF ] epoetin alfa ) sustain peripheral blood count ( first course therapy ) allow Concurrent steroid therapy ( ≤ 20 mg prednisone ) patient require chronic use disorder myeloma allow No concurrent combination antiretroviral therapy HIVpositive patient No concurrent investigational commercial agent therapy malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>